The HAGH Knockout HAP1 Polyclonal Cells product provides a CRISPR/Cas9-mediated gene disruption of the HAGH (glyoxalase II) locus in a polyclonal population of human HAP1 cells. This product is supplied as a pooled population of edited cells, enabling researchers to study the collective loss-of-function effects without clonal selection bias. The polyclonal format reflects the heterogeneous editing outcomes generated by CRISPR/Cas9 across the cell population, offering a robust model for analyzing HAGH-dependent phenotypes in a near-haploid genetic background.
HAP1 cells are a near-haploid human male cell line derived from the KBM-7 chronic myeloid leukemia (CML) cell line. They retain the BCR-ABL1 oncogenic fusion characteristic of CML and exhibit a stable haploid karyotype, which facilitates unambiguous gene editing and functional genomics studies. The haploid nature eliminates the complexity of heterozygous mutations, allowing direct genotype-phenotype correlations. This genetic simplicity, combined with the oncogenic background, makes HAP1 cells particularly well-suited for knockout screens and pathway interrogation.
HAGH encodes glyoxalase II, a critical enzyme in the glyoxalase pathway that catalyzes the hydrolysis of S-D-lactoylglutathione to glutathione and D-lactate. This reaction detoxifies methylglyoxal, a reactive dicarbonyl byproduct of glycolysis that forms advance glycation end products (AGEs). HAGH functions downstream of glyoxalase I (GLO1) and is regulated by the transcription factor NFE2L2 (Nrf2) under oxidative stress, as well as by HIF1A under hypoxic conditions. Its activity directly replenishes the intracellular glutathione pool and prevents methylglyoxal-induced protein and DNA glycation. Knockout of HAGH leads to accumulation of S-D-lactoylglutathione and methylglyoxal, elevation of oxidative stress markers, and increased AGE formation, providing a powerful tool to dissect the downstream consequences of glyoxalase pathway disruption.
The HAGH knockout in the HAP1 background is particularly valuable for investigating the interplay between oncogenic signaling and metabolic detoxification pathways. Given the BCR-ABL1-driven leukemic context, researchers can explore how methylglyoxal stress and glutathione metabolism influence cancer cell survival, proliferation, and drug sensitivity. The near-haploid genome ensures that the knockout phenotype is not masked by a second functional allele, yielding clear loss-of-function effects. This model enables precise assessment of HAGH-dependent responses to chemotherapeutics, methylglyoxal challenge, and oxidative stressors in a genetically tractable system.
Typical applications include investigating the role of glyoxalase II in diabetic complications, neurodegeneration, and aging, where methylglyoxal-mediated glycation is implicated. Researchers can employ this model for drug screening of glyoxalase inhibitors, utilizing assays such as glyoxalase II enzyme activity measurements, methylglyoxal quantification, glutathione redox ratio analysis, and AGE ELISA. The cells are also suitable for studying Nrf2-mediated stress responses, HIF1A signaling, and the functional crosstalk between glycolysis and detoxification pathways. Additional experiments may include cell viability assays under methylglyoxal stress and RT-qPCR profiling of pathway genes. The HAGH Knockout HAP1 Polyclonal Cells thus serve as a versatile platform for mechanistic studies and therapeutic target validation. For further information or technical support, please contact Ascent Research.
